Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin

European Journal of Pharmaceutical Sciences

Volumn 24, Issue 5, 2005, Pages 465-475

  Jolling, Koen ^a,d   Perez Ruixo, Juan Jose ^a   Hemeryck, Alex ^b   Vermeulen, An ^a   Greway, Tony ^c  

^a Adv PKPD Modeling Simulat Dept   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

Allometric scaling; Pegylated human erythropoietin; Population pharmacokinetics; Preclinical pharmacokinetics

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGYLATED RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ABSORPTION; ACCURACY; ANEMIA; ARTICLE; BODY WEIGHT; BRAIN WEIGHT; COMPARTMENT MODEL; COMPUTER PROGRAM; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MONKEY; NONHUMAN; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; RABBIT; RAT;

EID: 15244357228     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.01.002     Document Type: Article

References (20)

1. M. Allon, K. Kleinman, M. Walczyk, C. Kaupke, L. Messer-Mann, K. Olson, A. Heatherington, and B.J. Maroni Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis Clin. Pharmacol. Ther. 72 2002 546 555
2. S.L. Beal, A. Boeckmann, and L.B. Sheiner NONMEM Users Guides - Part I-VIII NONMEM Project Group C2555 1988-1998 University of California at San Francisco San Francisco
3. H. Boxenbaum Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics J. Pharmacokinet. Biopharm. 10 1982 411 426
4. H. Boxenbaum Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm Drug Metab. Rev. 15 1984 1071 1121
5. P. Caliceti, and P. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 55 2003 1261 1277
6. V. Cosson, E. Fuseau, C. Efthymiopoulos, and A. Bye Mixed effects modeling of sumatriptan pharmacokinetics during drug development. I. Interspecies allometric scaling J. Pharmacokinet. Biopharm. 25 1997 149 167
7. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095
8. R.L. Dedrick, K.B. Bischoff, and D.S. Zaharko Interspecies correlation of plasma concentration history of methotrexate Cancer Chemother. Rep. 54 1970 95 101
9. B. Efron, and R. Tibshirani An Introduction to the Bootstrap 1993 Chapman and Hall London, UK
10. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
11. J.M. Harris, N.E. Martín, and M. Modi Pegylation: a novel process for modifying pharmacokinetics Clin. Pharmacokinet. 40 2001 539 551
12. T.H. Hu, and W.L. Hayton Allometric scaling of xenobiotic clearance: uncertainty versus universality AAPS PharmSci. 3 2001 article 29
13. K. Jolling, J.J. Perez-Ruixo, A. Hemeryck, V. Piotrovskij, and T. Greway Population pharmacokinetic analysis of pegylated human erythropoietin in rats J. Pharm. Sci. 93 2004 3027 3038
14. M.J. Lindstrom, and T.M. Bates Nonlinear mixed effects models for repeated measures Biometrics 46 1990 673 687
15. I. Mahmood, and J.D. Balian Interspecies scaling: predicting clearance of drugs in humans: three different approaches Xenobiotica 26 1996 887 895
16. G.A. Sacher The lifespan of animal G.E.W. Wolstenholme M. O'connor Relation of Life Span to Brain Weight and Body Weight in Mammals 1959 Little Brown Boston 115
17. S-Plus Professional Release 2, 2000. Mathsoft, Inc., Data Analysis Products Division, Seattle, WA 98109, USA.
18. G.B. West, J.H. Brown, and B.J. Enquist A general model for the origin of allometric scaling laws in biology Science 276 1997 122 126
19. G.B. West, J.H. Brown, and B.J. Enquist The fourth dimension of life: fractal geometry and allometric scaling of organisms Science 284 1999 1677 1679
20. P.J. Williams, and E.I. Ette The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics' Clin. Pharmacokinet. 39 2000 385 395